Researchers Suggest Short Transition Period Between Natalizumab and Fingolimod Therapies to Control RRMS Disease Activity

    An international team led by researchers at the University Hospital Basel in Switzerland revealed that a short period of 8 to 12 weeks is the optimal timing to be considered when patients with relapsing-remitting multiple sclerosis (RRMS) are switched fromnatalizumab to fingolimod therapy. The study was recently published in the journalNeurology and is entitled “Switching from natalizumab to fingolimod, A randomized, placebo-controlled study in RRMS.”